Laura Nisenbaum, PhD, is a proven scientific leader with 30 years of biotechnology and academia experience. She is the Executive Director of Drug Development at the Alzheimer’s Drug Discovery Foundation (ADDF). Prior to joining ADDF, Dr. Nisenbaum served as Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen. Her time at Biogen followed 20 years of experience at Eli Lilly and Company in various roles including Asset Manager for Chorus, an autonomous early-phase clinical development unit within Lilly, Research Fellow and neuroscience lead in tailored therapeutics, translational medicine, and preclinical drug discovery. Prior to joining the biotechnology field, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in neuroscience in 1991 at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at NIH, the University of Tennessee College of Medicine, and a faculty position in Physiology and Neurobiology at the University of Connecticut.